Brockbank J, Wolowacz S. Economic evaluations of new oral anticoagulants for the prevention of venous thromboembolism after total hip or total knee replacement. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
Earnshaw S, Brogan A, Wolowacz S. Budget impact analysis II: applications & design issues. Presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy. Previously presented at the ISPOR 20th Annual International Meeting.
Pearson IV, Hawe E, Zuluaga S, Scuito S, Wolowacz S, Haiderali A. Cost-effectiveness of ofatumumab plus chlorambucil in first-line chronic lymphocytic leukemia in the United Kingdom. Poster presented at the 2015 ISPOR 18th Annual European Congress; November 2015. Milan, Italy.
Wolowacz S, Pearson I, Shannon P, Chubb B, Gundgaard J, Davies M, Briggs A. Development and validation of a cost-utility model for Type 1 diabetes mellitus. Diabet Med. 2015 Aug;32(8):1023-35. doi: 10.1111/dme.12663
Wolowacz S, Briggs A, Doward L. Measurement of health state utility values for economic models in clinical studies – findings of the good practices task force. Presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.
Earnshaw SR, Brogan AJ, Wolowacz SE. Budget impact analysis II: applications and design issues. Presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.
Muszbek N, Wolowacz S, Benedict A. Modeling in oncology: the taming of the shrews? Presented at the 2015 ISPOR 20th Annual International Meeting; May 2015. Philadelphia, PA.